On June 25, 2024, AstraZeneca reported that Imfinzi showed significant improvements in event-free and overall survival for muscle-invasive bladder cancer patients in the NIAGARA Phase III trial, demonstrating its potential as a new standard of care. The trial involved 1,063 patients and aimed to address high recurrence rates post-surgery.